BioSpace takes a look at a few of the highlights of the 24th annual meeting of the ASGCT, with researchers presenting cutting-edge work in the booming area of gene and cell therapy.

Mission Bio launched the company’s Pharma Assay Development (PAD) service, enabling its customers to obtain early access services based on the newest technologies as well as on existing products.

According to a research collaboration among UCLA investigators and Merck KGaA, berzosertib has shown promise for Covid-19 and is also being touted for the drug’s unusually broad effect in treating a range of cancers.

Manufacturing capacity and ingredients shortages are the main bottlenecks to expanding Covid-19 vaccine production, several global drug groups said on March 9, not patents that some critics are demanding be removed.

rBIO launched with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.

Thermo Fisher Scientific is significantly expanding the company’s footprint with new facilities in the United States and in Europe.

Five key genes are linked with the most severe form of Covid-19, scientists said, in research that also pointed to several existing drugs that could be repurposed to treat people who risk getting critically ill with the pandemic disease.

Inovio Pharmaceuticals Inc. received clearance from the U.S. health regulatory agency to begin a mid-stage study of the company’s Covid-19 vaccine candidate, the vaccine maker said.

Caris Life Sciences secured $310 million in growth capital that will be used to expand the molecular science company’s presence in precision medicine in oncology.

Bayer is making a big bet on gene therapy with the acquisition of North Carolina-based Asklepios BioPharmaceutical (AskBio).